Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action

Table 1 Differences in the mortality rate and noradrenaline-free days between the patients in the PMX-HP-treated group and the control group stratified by SOFA score

	28-day mortality range (%) Fatality/the number of patients (n)			Noradrenaline-free days Median (IQR)
SOFA score range	PMX-HP group	Control group	p-value	PMX-HP group	Control group	p-value
0–6	15.0–15.2 (69/456)	9.1–16.7 (47/407)	NS	25 (21-–6)	25 (20–26)	0.9287
7–9	14.2–16.1 (83/553)	16.2–22.9 (92/463)	0.0410	25 (20–26)	24 (11–26)	0.0003
10–12	14.8–25.3 (95/510)	25.3–30.6 (145/529)	0.0008	24 (15–26)	22(0–6)	0.0005
13–15	28.5–39.3 (116/356)	24.8–35.5 (118/404)	NS	22 (0–25)	21.5 (0–25)	0.9161
16–24	30.6–61.5 (62/158)	34.6–57.1 (96/230)	NS	14 (0–24)	15 (0–4)	0.3491

Twenty-eight-day mortality range represents the minimum and the maximum number. IQR denotes interquartile range and NS not significant

ISSN: 2731-3786